EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial

Lidan Zhang, Di Wu, Liang Li, Qin Zhao, Hailing Yang, Xiaoyong Han, Liang Liu, Lu Gao

Journal of Cardiothoracic Surgery · 2025

DOI: 10.1186/s13019-024-03225-5 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiothoracic Surgery, 2025. Verfasst von Lidan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Baoding First Central Hospital, Baoding, 071000, China. Hauptthemen laut MEDLINE: Rivaroxaban, Venous Thrombosis, Lung Neoplasms, Heparin, Low-Molecular-Weight. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Baoding City Key Laboratory of Diagnosis and Treatment of Pulmonary Nodules.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To assess the effectiveness and safety profiles of rivaroxaban compared to low molecular weight heparin (LMWH) in managing lower extremity deep vein thrombosis (DVT) subsequent to thoracoscopic lung cancer surgery. METHODS: Sixty patients diagnosed with lower extremity deep vein thrombosis (DVT) following thoracoscopic lung cancer surgery were randomly assigned to two groups: the experimental group comprising 30 patients treated with rivaroxaban, and the control group consisting of 30 patients treated with low molecular weight heparin (LMWH). The fundamental clinical characteristics of patients in both groups were documented, encompassing parameters, along with pre- and post-surgical lower limb vascular ultrasound findings. Additionally, variations in drainage volume over the initial three days following the procedure were also noted. Patients were subjected to a three-month follow-up period, during which data from one-month and three-month postoperative examinations were collected. RESULTS: Patients from both groups exhibited satisfactory wound healing postoperatively. D-dimer levels remained stable, and lower extremity vascular ultrasound evaluations showed no signs of additional thrombus formation. Moreover, there were no reported cases of distant postoperative complications such as pleural effusion, gingival bleeding, or gastrointestinal bleeding. Nonetheless, subcutaneous bruising was observed in six patients from the control group, all localized at the sites of LMWH injections. CONCLUSION: Rivaroxaban demonstrates efficacy comparable to LMWH in patients with lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery, while exhibiting a superior safety profile compared to LMWH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanVenous ThrombosisLung NeoplasmsHeparin, Low-Molecular-WeightLower ExtremityPostoperative ComplicationsThoracoscopyHumansMaleFemaleMiddle AgedAgedFactor Xa InhibitorsTreatment OutcomeAnticoagulants

Stichwörter der Autor:innen

D-dimerLow molecular weight heparinLower extremity deep vein thrombosisPost-thoracoscopic lung cancerRivaroxaban

Substanzen

RivaroxabanHeparin, Low-Molecular-WeightFactor Xa InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Baoding First Central Hospital, Baoding, 071000, China.
  • Department of Thoracic Surgery, Baoding First Central Hospital, Baoding, 071000, China.
  • Department of Thoracic Surgery, Baoding First Central Hospital, Baoding, 071000, China. 765902992@qq.com.

Förderung

  • Baoding City Key Laboratory of Diagnosis and Treatment of Pulmonary Nodules

Zitieren

APA

Zhang, L., Wu, D., Li, L., Zhao, Q., Yang, H., Han, X., Liu, L., & Gao, L. (2025). Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial. Journal of Cardiothoracic Surgery. https://doi.org/10.1186/s13019-024-03225-5

Vancouver

Zhang L, Wu D, Li L, Zhao Q, Yang H, Han X, et al. Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial. Journal of Cardiothoracic Surgery. 2025. doi:10.1186/s13019-024-03225-5

BibTeX
@article{Zhang2025,
  author = {Zhang, Lidan and Wu, Di and Li, Liang and Zhao, Qin and Yang, Hailing and Han, Xiaoyong and Liu, Liang and Gao, Lu},
  title = {Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial},
  journal = {Journal of Cardiothoracic Surgery},
  year = {2025},
  doi = {10.1186/s13019-024-03225-5}
}
Kostenlos starten →